February 27, 2020 / 12:29 PM / in a month

BRIEF-Mapkure, Beigene And Springworks Announce Initiation Of Early-Stage Trial Of Refractory Solid Tumors Treatment

Feb 27 (Reuters) - Springworks Therapeutics Inc:

* MAPKURE, BEIGENE AND SPRINGWORKS ANNOUNCE INITIATION OF PHASE 1 CLINICAL TRIAL OF BGB-3245, A SELECTIVE NEXT-GENERATION B-RAF INHIBITOR, IN ADULT PATIENTS WITH ADVANCED OR REFRACTORY SOLID TUMORS

* MAPKURE - INDUSTRY-LEADING SCIENTIFIC ADVISORY BOARD FORMED TO SUPPORT ADVANCEMENT OF BGB-3245

* MAPKURE - FDA ALLOWED IND APPLICATION SUBMITTED FOR BGB-3245 TO PROCEED, WHICH WILL ENABLE STUDY EXPANSION TO U.S. SITES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below